Purchase this article with an account.
Tomoko Tsukahara, Masahiko Kozawa, Eiichi Uchio; Treatment outcome of systemic cyclosporine in occular lesion.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1880.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Cyclosporin (CsA) is commonly used as instillation therapy in vernal keratoconjuctivitis and is already known as an alternative systemic therapy instead of corticosteroid in Behcet disease. We report treatment outcome of systemic CsA at Fukuoka University in the past 8 years.
This study was carried out in cases we used systemic CsA was used as oral administration from 2005 to 2012 in our institution.
Number of patients who was used systemic CsA totaled 18 cases. Eight cases were replaced penetrating keratoplasty ( PKP ), 3 cases were given first PKP caused by limbal dysfuncton, 2 cases were Behcet disease, 2 cases were idiopathic uveitis with corticosteroid responder, 1 case was intractable Vogt-Koyanagi-Harada disease, Mooren ulcer and first PKP with atopic dermatitis, respectively. Readministration did not needed except for PKP and corneal limbal transplantation. In some cases of replaced PKP and corneal limbal transplantation, multiple surgeries were necessary afterwards. In three cases with symptoms thought to be side effects of systemic CsA, the main symptoms were general fatigue, loss of appetite and renal disorder, consequently we needed to reduce or discontinue the medication. No case developed infections such as herpetic keratitis.
In cases of uveitis, systemic CsA is available to restrain inflammation without raising intraocular pressure. On the other hand, it is difficult to completely control the rejection only systemic CsA in cases of replaced PKP. Therefore prediction and protection of the rejection should be investigated.
This PDF is available to Subscribers Only